Results 131 to 140 of about 18,742 (250)

Trends in Second‐Line Initiations and Treatment Outcomes Across Age and Frailty Groups in People With Type 2 Diabetes: UK Population‐Based Study, 2019–2024

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7471-7482, August 2026.
ABSTRACT Aims To assess contemporary UK trends in second‐line treatment initiations and outcomes across age‐and‐frailty groups in people with type 2 diabetes (T2D). Materials and Methods We studied 117 046 UK adults with T2D initiating second‐line therapy between 2019–2024 (Clinical Practice Research Datalink).
M. M. Dinsdale, K. G. Young, P. Cardoso, L. M. Güdemann, T. T. Jansz, A. P. McGovern, A. G. Jones, E. R. Pearson, A. T. Hattersley, T. J. McKinley, B. M. Shields, J. M. Dennis   +11 more
wiley   +1 more source

Association of SGLT2 inhibitors use with a lower risk of biliary diseases in patients with type 2 diabetes mellitus: a retrospective cohort study. [PDF]

Ann Med
Gao M, Lin Q, Hu K, Zhong B, Zhu T, Gong Z, Zhang K, Chen X, Chen X, Zhang Y, Li Y, Tang S, Su D, Liang X, Liu Y.   +14 more
europepmc   +1 more source

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review

Obesity Reviews, Volume 27, Issue 8, August 2026.
ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira, ZhiDi Deng, Manfred J. Muller, Giovanna G. L. Bergamasco, Sarah Cawsey, Melania Manco, Steven B. Heymsfield, Carla M. Prado, Andrea M. Haqq   +8 more
wiley   +1 more source

Hepatogenous diabetes in the era of precision medicine: diagnosis, management, and future directions. [PDF]

Clin Exp Med
El-Azab G, Rady MA, Assem M, Nagdy H.
europepmc   +1 more source

Patterns and Trends of Glucose‐Lowering Therapy in Alzheimer's Disease and Related Dementias

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7592-7596, August 2026.
Huilin Tang, Bingyu Zhang, Yiwen Lu, Ying Lu, Anastassia Amaro, Yuan Lu, David A. Wolk, Yong Chen   +7 more
wiley   +1 more source

Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation. [PDF]

BMJ Open Diabetes Res Care
Sklepinski S, Ratzki-Leewing AA, Herrin J, Swarna KS, Deng Y, Polley EC, Neumiller JJ, Galindo RJ, Umpierrez GE, Ross JS, Brito JP, Montori VM, Borah BJ, Maron BA, Mickelson MM, McCoy RG.   +15 more
europepmc   +1 more source

Autoimmune Disease Risk With GLP‐1RA, DPP‐4i, and SGLT2i Treatment in Patients With Diabetes

ACR Open Rheumatology, Volume 8, Issue 7, July 2026.
Objective Dipeptidyl peptidase‐4 inhibitors (DPP‐4i), glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are widely used for type 2 diabetes, yet their comparative immunologic safety is uncertain.
Arjun Mahajan, David W. Bates, Alessandro Doria, Dinah Foer, Avery H. LaChance, Jeffrey A. Sparks   +5 more
wiley   +1 more source

Glaucoma Risk with Metformin and Sulfonylurea Therapies in Type 2 Diabetes: A Retrospective Cohort Study. [PDF]

Clin Ophthalmol
Lim J, Zhou J, Wu H, Liu Z, Lee DA.
europepmc   +1 more source

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 168-177, July 2026.
Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin, Jia‐Jin Chen, Ching‐Chung Hsiao, Yu‐Wei Fang, Meng‐Ting Chen, Ming‐Hsien Tsai, Huang‐Yu Yang   +6 more
wiley   +1 more source

A paradigm shift in diabetes care: clinical implications of once-weekly insulin icodec. [PDF]

Ann Med Surg (Lond)
Abid MA, Abid MH, Afzal MD.
europepmc   +1 more source